-+ 0.00%
-+ 0.00%
-+ 0.00%

CEL-SCI's Multikine Gains Saudi Accelerated Review Designation for Potential 2027 Launch

PUBT·11/20/2026 11:04:24
Listen to the news
CEL-SCI's Multikine Gains Saudi Accelerated Review Designation for Potential 2027 Launch
  • CEL-SCI announced November 20, 2026, that investigational cancer immunotherapy Multikine received Saudi Food and Drug Authority designation for accelerated review.
  • A marketing application is planned within two to three months; the pathway provides a target assessment period of 160 working days.
  • Saudi Arabia could become Multikine’s first commercial market, with sales potentially starting in 2027 or early 2028, subject to regulatory approval.
  • Local partner Amarox holds exclusive Saudi distribution rights under a 50%/50% net revenue-sharing agreement.
  • Phase 3 results already reported showed improved survival versus standard care alone in the targeted population of previously untreated oral cancer patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-010013), on November 20, 2026, and is solely responsible for the information contained therein.